Predicting the effects of dATP on cardiac contraction using multiscale modeling of the sarcomere
- PMID: 32956632
- PMCID: PMC7721865
- DOI: 10.1016/j.abb.2020.108582
Predicting the effects of dATP on cardiac contraction using multiscale modeling of the sarcomere
Abstract
2'-deoxy-ATP (dATP) is a naturally occurring small molecule that has shown promise as a therapeutic because it significantly increases cardiac myocyte force development even at low dATP/ATP ratios. To investigate mechanisms by which dATP alters myosin crossbridge dynamics, we used Brownian dynamics simulations to calculate association rates between actin and ADP- or dADP-bound myosin. These rates were then directly incorporated in a mechanistic Monte Carlo Markov Chain model of cooperative sarcomere contraction. A unique combination of increased powerstroke and detachment rates was required to match experimental steady-state and kinetic data for dATP force production in rat cardiac myocytes when the myosin attachment rate in the model was constrained by the results of a Brownian dynamics simulation. Nearest-neighbor cooperativity was seen to contribute to, but not fully explain, the steep relationship between dATP/ATP ratio and steady-state force-development observed at lower dATP concentrations. Dynamic twitch simulations performed using measured calcium transients as inputs showed that the effects of dATP on the crossbridge alone were not sufficient to explain experimentally observed enhancement of relaxation kinetics by dATP treatment. Hence, dATP may also affect calcium handling even at low concentrations. By enabling the effects of dATP on sarcomere mechanics to be predicted, this multi-scale modeling framework may elucidate the molecular mechanisms by which dATP can have therapeutic effects on cardiac contractile dysfunction.
Keywords: Brownian dynamics; Cardiac contractility; Multiscale modeling; Myosin; Sarcomere.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declarations of interest
A. D. McCulloch is a co-founder of and has an equity interest in Insilicomed and Vektor Medical. He serves on the scientific advisory board of Insilicomed and as scientific advisor to both companies. Some of his research grants, including those acknowledged here, have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to these companies.
Figures





References
-
- Regnier M, Rivera AJ, Chase PB, 2-deoxy-ATP enhances contractility of rat cardiac muscle, Circ Res 86 (2000) 1211–1217. - PubMed
-
- Thomson KS, Odom GL, Murry CE, Mahairas GG, Moussavi-Harami F, Teichman SL, Chen X, Hauschka SD, Chamberlain JS, Regnier M, Translation of cardiac myosin activation with 2-deoxy-ATP to treat heart failure via an experimental ribonucleotide reductase-based gene therapy, Biophys J 1 (7) (2016) 666–679. - PMC - PubMed